Collaboration combines Bonito’s proprietary functional delivery data engine and ligand discovery platform with DaltonTx’s adaptive AI technology to accelerate precision oligotherapeutic delivery, beginning in the CNS WALTHAM, Mass. and LONDON, May 27, 2026 (GLOBE NEWSWIRE) — Bonito Biosciences (“Bonito”), a biotechnology company building the data foundation for programmable oligotherapeutic delivery, and”) DaltonTx, the intelligence backbone […]…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.